10:50 AM EST, 03/07/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday it received approval from the UK's Medicines and Healthcare products Regulatory Agency for Alyftrek to treat cystic fibrosis in patients six years and older with at least one F508del or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene.

Alyftrek is a triple combination cystic fibrosis transmembrane conductance regulator modulator treatment, the company added.

The US Food and Drug Administration approved Alyftrek in December 2024.

Price: 488.10, Change: +2.38, Percent Change: +0.49